NCT05373355 - Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 10, 2022

Primary Completion Date

September 7, 2023

Study Completion Date

September 7, 2023

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG

TLL018 tablets

Oral tablets administered at different doses BID daily for 12 weeks.

Trial Locations (1)

Hospital For Skin Diseases,Institute of Dermatology Chinese Academy of Medical Sciences, Peking Union Medical College, Nanjing